"

On this episode, we’re hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"

On this episode, we’re hearing from authors of recent impactful research in the field of genitourinary oncology.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we’ll hear about the results of the IMmotion 010 study of adjuvant atezolizumab for renal cell carcinoma post-nephrectomy.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement

Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.